U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07524946) titled 'Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo' on Feb. 05.
Brief Summary: This study is to evaluate the safety, pharmacokinetics, and treatment effect for topically applied CABTREO lotion in pediatric participants ages 9 to 11 years, 11 months with Acne Vulgaris.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Acne Vulgaris
Intervention:
DRUG: CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.
The study drug will be applied topically to the treatment areas at home, each the morning, for a period of 12 weeks, with the exception of stud...